PAVmed Inc. (NASDAQ:PAVM)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $5.55, but opened at $4.48. PAVmed shares last traded at $4.61, with a volume of 49,609 shares changing hands.

A number of research analysts have recently issued reports on PAVM shares. Ascendiant Capital Markets started coverage on PAVmed in a report on Thursday, November 5th. They set a “buy” rating and a $5.00 price target on the stock. Lake Street Capital upped their price target on PAVmed from $5.00 to $9.00 and gave the company a “buy” rating in a report on Monday.

The business has a fifty day simple moving average of $2.59 and a two-hundred day simple moving average of $2.08. The company has a market cap of $329.32 million, a P/E ratio of -5.46 and a beta of 0.13.

PAVmed (NASDAQ:PAVM) last posted its earnings results on Sunday, February 21st. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06).

Institutional investors and hedge funds have recently modified their holdings of the business. Financial Advocates Investment Management purchased a new stake in PAVmed in the third quarter worth about $35,000. CIBC Private Wealth Group LLC purchased a new stake in PAVmed in the third quarter worth about $65,000. Vigilare Wealth Management increased its position in PAVmed by 19.8% in the fourth quarter. Vigilare Wealth Management now owns 186,900 shares of the company’s stock worth $396,000 after buying an additional 30,900 shares in the last quarter. AQR Capital Management LLC purchased a new stake in PAVmed in the third quarter worth about $148,000. Finally, Squarepoint Ops LLC increased its position in PAVmed by 179.3% in the third quarter. Squarepoint Ops LLC now owns 29,264 shares of the company’s stock worth $52,000 after buying an additional 18,787 shares in the last quarter. Institutional investors and hedge funds own 14.14% of the company’s stock.

PAVmed Company Profile (NASDAQ:PAVM)

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.

See Also: Equal Weight Rating

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.